Outpatient Management of Cellulitis
For typical uncomplicated cellulitis without systemic signs of infection, treat with oral antibiotics active against streptococci (such as cephalexin, dicloxacillin, or amoxicillin) for 5 days, elevate the affected limb, and address predisposing factors like tinea pedis—cultures are not routinely needed. 1
Patient Selection for Outpatient Management
Outpatient therapy is appropriate for patients who lack:
- SIRS (systemic inflammatory response syndrome)
- Altered mental status
- Hemodynamic instability
- Concern for deeper or necrotizing infection 1
Hospitalize if any of these red flags are present, or if the patient has poor adherence potential or severe immunocompromise.
Antibiotic Selection Algorithm
For Typical Cellulitis (No Risk Factors for MRSA)
First-line oral antibiotics targeting streptococci:
- Cephalexin
- Dicloxacillin
- Amoxicillin
- Amoxicillin-clavulanate
- Penicillin
- Clindamycin 1
The IDSA guidelines strongly recommend streptococcal coverage because MRSA is an uncommon cause of typical cellulitis—one prospective study showed 96% success with beta-lactams alone 1. A recent double-blind trial confirmed that adding TMP-SMX to cephalexin provided no additional benefit for pure cellulitis 1.
When to Add MRSA Coverage
Add MRSA-active antibiotics if cellulitis is associated with:
- Penetrating trauma (especially injection drug use)
- Purulent drainage
- Evidence of MRSA infection elsewhere
- Known MRSA nasal colonization
- SIRS 1
Oral MRSA-active options:
- Clindamycin (covers both streptococci and MRSA)
- TMP-SMX + beta-lactam (e.g., cephalexin or amoxicillin)
- Doxycycline + beta-lactam 1
In high MRSA-prevalence areas, one retrospective study showed TMP-SMX had 91% success versus 74% for cephalexin 2, though this conflicts with the IDSA's position that beta-lactam monotherapy remains appropriate for pure cellulitis without purulence.
Treatment Duration
5 days of antibiotics is sufficient if clinical improvement has occurred by day 5 (strong recommendation, high-quality evidence) 1. Extend treatment only if infection has not improved within this timeframe.
Essential Non-Pharmacological Management
Immediate Measures
- Elevate the affected limb to promote gravity drainage of edema and inflammatory mediators 1
- Mark the borders of erythema to track progression or improvement
Address Predisposing Factors
- Examine interdigital toe spaces carefully for tinea pedis, fissuring, scaling, or maceration—treating these reduces recurrence risk 1
- Treat underlying venous insufficiency, lymphedema, or "stasis dermatitis" 1
- Address obesity, trauma sites, or other local risk factors 1
Diagnostic Testing
Routine cultures are NOT recommended for typical cellulitis (strong recommendation) 1.
Obtain blood cultures AND consider tissue aspirate/biopsy cultures in:
- Malignancy with chemotherapy
- Neutropenia
- Severe cell-mediated immunodeficiency
- Immersion injuries
- Animal bites 1
Special Considerations
Systemic Signs Present (Moderate Cellulitis)
If fever or other systemic signs exist but patient remains stable for outpatient care, many clinicians include MSSA coverage (though this is a weak recommendation) 1.
Adjunctive Corticosteroids
Systemic corticosteroids (e.g., prednisone 40 mg daily for 7 days) could be considered in non-diabetic adult patients, though this is a weak recommendation 1.
Recurrence Prevention
For patients with recurrent cellulitis:
- Aggressive management of tinea pedis and toe web abnormalities reduces recurrence from 40% to 15% with compression therapy 3
- Consider 5-day decolonization regimen: intranasal mupirocin twice daily + daily chlorhexidine washes (weak recommendation) 1
- Long-term antibiotic prophylaxis may be needed for frequent recurrences despite addressing local factors 1
Common Pitfalls
- Don't reflexively cover MRSA in typical cellulitis without purulence or risk factors—this leads to unnecessary broad-spectrum use 1
- Don't treat for 10-14 days when 5 days is equally effective if improvement occurs 1
- Don't forget to examine the feet—untreated tinea pedis is a major driver of recurrence 1
- Don't assume worsening in first 24-48 hours means treatment failure—this may reflect inflammatory mediator release from bacterial destruction 1
Emerging Evidence
Recent data suggest oral beta-lactam therapy with flucloxacillin plus probenecid has similar outcomes to outpatient parenteral therapy (OPAT) with IV cefazolin, with comparable 28-day admission rates (12.9% vs 12.2%) and tolerability 4. This supports the shift toward oral therapy when feasible, avoiding the complexity and cost of OPAT programs.